Company news
Oncosil Medical Ltd (ASX:OSL) news
Every Oncosil Medical Ltd press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
OSL Secures $5.6 million from Major Institutional Investors
September 7, 2026
OncoSil Receives FDA Approval for Distal Cholangiocarcinoma
August 16, 2026
OncoSil Medical Completes Manufacturing Validation
July 12, 2026
OncoSil Medical Files for FDA Approval
July 2, 2026
OncoSil Selected for Major European Pancreatic Cancer Study
July 1, 2026
OncoSil progresses HDE with US FDA
June 8, 2026
OncoSil Medical Receives TGA Approval in Australia
May 19, 2026
Security Class Reinstatement to Quotation - OSLOE
March 17, 2026
Security Class Suspension from Quotation
March 10, 2026
Appendix 4D and Half Year Accounts
February 23, 2026
CEO Remuneration Update
February 11, 2026
Capital Raising Presentation
February 3, 2026
$8.0 million Capital Raise for Ongoing Commercial Expansion
February 3, 2026
Prospectus
February 3, 2026
Quarterly Activities/Appendix 4C Cash Flow Report
January 29, 2026
Trading Halt
January 29, 2026
OncoSil receives $1.84m R&D tax incentive
January 7, 2026
OSPREY Analysis Shows Survival Benefit for OncoSil Patients
December 2, 2025
Response to ASX Aware Letter
September 29, 2025
Positive Preliminary Results from PANCOSIL Phase 1-2 Study
September 17, 2025
Appendix 4E and Annual Report
August 29, 2025
Completion of Recruitment in TRIPP-FFX Clinical Trial
July 22, 2025
Completion of Recruitment in PANCOSIL Study
July 3, 2025
OSL announces $8.7m capital raise to drive commercialisation
May 26, 2025
Consolidation/Split - OSL
May 1, 2025
120 German Hospitals entitled to negotiate fee for OncoSil
February 3, 2025
OncoSil Medical Receives MDR Approval
January 27, 2025
OncoSil receives $1.05m R&D tax incentive
January 8, 2025
Oncosil completes $1 million Share Purchase Plan (SPP)
December 12, 2024
Prospectus 2024 Share Purchase Plan (SPP) Offer
November 5, 2024
OSL completes $7 M Placement and announces $1 M SPP
October 27, 2024
G-BA Approval received for OncoSil Device
October 23, 2024
Appendix 4E Preliminary Financial Report
August 29, 2024
Successful Treatment with OncoSil Device in Turkiye
August 15, 2024
Australian institution to invest $2.7 million in OSL
July 24, 2024
$5.3 million raised under Entitlement Offer
May 2, 2024
1st Study in Man Increases Pancreatic Tumor Vascularity
April 30, 2024
First patient treated with OncoSil device in Turkiye
April 15, 2024
First patient treated in the UK for the TRIPP-FXX study
April 11, 2024
First Austria-based treatments utilising the OncoSil device
April 4, 2024
Prospectus - Entitlement Offer
March 24, 2024
Placement and Entitlement Offer to raise up to $7.1 million
March 19, 2024
84 German hospitals can negotiate fee for Oncosil device
January 31, 2024
OncoSil receives $1.1m R&D tax incentive
December 14, 2023
First two commercial patient treatments in Greece
December 7, 2023
OncoSil onboards first patient in PANCOSIL Clinical Trial
November 28, 2023
Multi-Centre Data on OncoSil in Metastatic Pancreatic Cancer
June 30, 2023
Ethics Committee Approves PANCOSIL Clinical Trial
June 4, 2023
First patient treatment in Italy
May 21, 2023
First patient enrolled in the TRIPP-FFX Clinical Study
May 2, 2023